资源描述：
《成人慢性髓性白血病骨髓细胞内IL21受体拮抗剂的表达及.pdf》由会员上传分享，免费在线阅读，更多相关内容在行业资料-天天文库。
1、·34·中国实验血液学杂志JournalofExperimentalHematology2003;11(1):34-37文章编号(ArticleID):1009-2137(2003)01-0034-04·论著·成人慢性髓性白血病骨髓细胞内IL21受体拮抗剂的表达及意义阮国瑞,陈珊珊,王 卉,刘艳荣,常 艳,付家瑜,李金兰,秦亚溱北京大学血液病研究所、人民医院,北京100044摘要 为了研究细胞内白细胞介素1受体拮抗剂(intracellularinterleukin21receptorantagonist,icIL21ra
2、)在成人慢性髓性白血病(chronicmyeloidleukemia,CML)骨髓细胞不同群体细胞内的表达及意义,本研究利用15种不同荧光标记的单克隆抗体,将骨髓细胞分成不同的群体,通过流式细胞术检测未治的,经STI571(signaltransductioninhibitor571)或其它药物治疗的CML慢性期(chronicphase,CP)和加速P急变期(acceleratedorblasticphase,APPBP)病人及正常人骨髓不同群细胞中icIL21ra的表达。结果显示:①IL21ra表达于CML病人及正常人所
3、有的有核细胞内,但各群细胞的表达量不同,以粒细胞表达量最高,淋巴细胞表达量最低;②17例未治CML病人骨髓总有核细胞、粒细胞、淋巴细胞icIL21ra平均荧光强度明显低于8例正常人组;③13例骨髓幼稚细胞数大于或等于10%的CML2APPBP病人骨髓总有核细胞、粒细胞及淋巴细胞icIL21ra平均荧光强度明显低于43例幼稚细胞数小于5%或9例幼稚细胞数为5%-10%的CML2CP病人。结论:CML病人骨髓总有核细胞与正常人相比icIL21ra表达降低。icIL21ra在CML病人骨髓总有核细胞表达量降低可能是CML疾病进展的
4、因素之一。关键词 慢性髓性白血病;骨髓细胞;白细胞介素1;白细胞介素1受体拮抗剂中图分类号 R733172文献标识码 ATheSignificanceofIntracellularIL21raExpressionintheBoneMarrowCellsfromAdultChronicMyelogenousLeukemiaRUANGuo2Rui,CHENShan2Shan,WANHui,LIUYan2Rong,CHANGYan,FUJia2Yu,LIJin2Lan,QinYa2ZhenInstituteofHematol
5、ogyandPeople′sHospital,PekingUniversity,Beijing100044,ChinaAbstractToestimateintracellularinterleukin21receptorantagonist(icIL21ra)expressioninthebonemarrowcellsfromadultpatientswithchronicmyelogenousleukemia(CML),flowcytometry(FCM)assaywasusedfordetectingthemeanic
6、IL21rafluorescenceintensitypercell(equivalenttoit′sexpressionlevel)indifferentgroupsofcellsfromnormalandCMLpatientbonemarrowsby15monoclonalantibodieswithdifferentfluorescentmarker.TheresultsshowedthatallofmarrownucleatedcellsexpressIL21ra,butitsexpressionlevelingra
7、nulocyteswasthehighestandthatinlymphocyteswasthelowest.TheicIL21raexpressionlevelwassignificantlylowerinnucleatedmarrowcells,granulocytesandlymphocytesfromthemarrowof17untreatedCMLpatientsthanthatfromthemarrowof8normal.ThemeanicIL21rafluorescenceintensitywassignifi
8、cantlylowerinmarrownucleatedcells,granulocytesandlymphocytesin13CMLpatientswithmarrowblasts≥10%thanthatin43CMLpatientswithmarrowblasts<5%orthanth
